NorthSea Therapeutics B.V. has achieved significant regulatory milestones with the US FDA and the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) granting Orphan Drug Designations (ODD) to orziloben (NST-6179) for the treatment of intestinal failure associated liver disease (IFALD). This recognition underscores the urgent need for effective treatments in the realm of rare liver diseases, particularly as orziloben is currently undergoing a Phase 2 study targeting this life-threatening condition.
Sophie Jeannin, Chief Medical Officer of NorthSea Therapeutics, emphasized the importance of these designations, noting that orziloben’s potential could redefine treatment standards for IFALD, a chronic ailment with no existing pharmacologic options. The ongoing Phase 2 trial aims to assess the drug’s safety and efficacy, with topline results anticipated by the third quarter of 2026.
IFALD is a severe complication for patients with chronic intestinal failure who rely on parenteral nutrition, affecting a significant number of adults and children in the United States. Orziloben’s unique mechanism, as a synthetic medium chain fatty acid analog, allows it to effectively target liver dysfunction and inflammation, potentially transforming the treatment landscape for this patient population. NorthSea’s commitment to advancing orziloben reflects a broader strategy to address the unmet medical needs in the field of rare liver diseases.
Get started today with Solo access →
